Has Josefa Binker received payments from drug or device companies?

Yes. Drug and device makers reported $3,464 in general payments to Josefa Binker across 35 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Josefa Binker did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Josefa Binker come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Josefa Binker

Family Medicine · Homestead, FLNPI 1487603353

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,536 of the $3,464 with a category attached, or 73.2%. 13 manufacturers reported payments, led by Janssen Research & Development, LLC at 35.8% of the total. Reporting peaked in 2019 at $1,552 and has fallen 98.4% since, to $24 in 2024.

$3,464in general payments, 2019–2025

Across 35 payments — averaging $98.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Janssen Research & Development, LLC$1K
AstraZeneca$462
Novo Nordisk$351
GSK$247
AbbVie$242
Astrazeneca UK Limited$181
plus $743 from 7 others

$131,804in research payments, 2019–2025

Across 33 payments — averaging $3994.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Astrazeneca UK Limited$41K
Sanofi US Services Inc.$38K
Janssen Research & Development, LLC$36K
Pfizer$10K
Regeneron$6K

What the payments were for

Travel & lodging$92827%
Food & beverage$2,53673%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Janssen Research & Development, LLC	11	$1,239
AstraZeneca	4	$462
Novo Nordisk	3	$351
GSK	2	$247
AbbVie(2 entities)	6	$242
Astrazeneca UK Limited	1	$181
Boehringer Ingelheim	1	$125
Esperion Therapeutics, Inc.	1	$125
Radius Health, Inc.	1	$115
Amarin Pharma, Inc.	1	$102
Lilly USA, LLC	2	$94
Sanofi-aventis U.S. LLC	1	$93
Johnson & Johnson	1	$89

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,464 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida →

Other family medicine in Homestead

Noah LeeOakland Park$1.2M
Angela RosselotBelle Isle$977K
Richard LappOrlando$702K
Hal BrownVero Beach$477K
Lisa EvansBoca Raton$473K
Giovana Rene CrooksBoca Raton$407K
Edward BraunSt Petersburg$364K
Samuel GreenleePensacola$235K
Kevin FitzgeraldStuart$198K
Louis KuritzkyGainesville$186K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →